ストックスクリーナーアプリを入手
5.10
2.11%
-0.11
前日終値:
$5.21
開ける：
$5.18
24時間の取引高:
280.83K
Relative Volume:
0.56
時価総額：
$185.09M
収益：
$10.00M
当期純損益:
$-75.99M
株価収益率:
-2.1363
EPS:
-2.3873
ネットキャッシュフロー:
$-80.36M
1週間 パフォーマンス:
-3.23%
1か月 パフォーマンス:
-39.93%
6か月 パフォーマンス:
-79.91%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$4.94
$5.70
52週間の値動き範囲:
$4.94
$33.20
Evommune Inc Stock (EVMN) Company Profile
Compare EVMN vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
5.10 | 185.09M | 10.00M | -75.99M | -80.36M | -2.3873 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-10-20 | 再開されました | Morgan Stanley | Overweight |
| 2026-10-12 | 開始されました | UBS | Neutral |
| 2026-08-26 | 開始されました | Needham | Buy |
| 2026-06-30 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2026-06-29 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2026-05-01 | 開始されました | Stifel | Buy |
| 2026-04-07 | 再開されました | Oppenheimer | Outperform |
| 2026-01-22 | 開始されました | Oppenheimer | Outperform |
| 2026-01-08 | 開始されました | Raymond James | Strong Buy |
| 2026-01-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 開始されました | Evercore ISI | Outperform |
| 2025-12-01 | 開始されました | Leerink Partners | Outperform |
| 2025-12-01 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-01 | 開始されました | William Blair | Outperform |
すべてを表示
Evommune Inc (EVMN) 最新ニュース
Evommune stock initiated at Overweight by Morgan Stanley on dermatitis drug potential - Investing.com
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Evommune, Inc. $EVMN Stock: Andera Partners Decreases Stake - MarketBeat
Evommune, Inc. (EVMN) options chain - Yahoo Finance Australia
Form 4 Evommune Inc: Luis C. Pena (Director, President & CEO) For: 30 September - Investing.com India
Form 4 Evommune Inc: Luis C. Pena (Director, President & CEO) For: 30 September By Investing.com - Investing.com South Africa
At 85% of the closing price, Evommune (EVMN) CEO acquires 1,115 shares through an employee plan. - Stock Titan
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS Group - MarketBeat
Evommune, Inc. (EVMN) Receives a Hold from UBS - The Globe and Mail
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target - Moomoo
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target - Yahoo Finance
UBS Initiates Evommune(EVMN.US) With Hold Rating, Announces Target Price $8 - Moomoo
UBS initiates Evommune stock coverage with neutral rating on AD potential - Investing.com Nigeria
Long-acting EVO301 Shows Promise in Proof-of-concept AD Study - The Dermatology Digest
Evommune Inc (EVMN-N) Stock Price and News - The Globe and Mail
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - BioSpace
Evommune presents Phase 2a atopic dermatitis trial data - Investing.com
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Yahoo! Finance Canada
Evommune (NYSE:EVMN)Stock Analysis - Simply Wall Street
Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $33.33 According to Analysts - MarketBeat
Evommune Reports Phase 2a EVO301 Atopic Dermatitis Data at EADV 2026 via 8-K Filing - Kalkine Media
Evommune to present phase 2a atopic dermatitis data at EADV By Investing.com - Investing.com Nigeria
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Yahoo Finance Australia
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Yahoo Finance
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF) - The Globe and Mail
Cantor Fitzgerald reiterates Evommune stock rating at Overweight - Investing.com
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - Yahoo Finance
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027–2028 milestones - TradingView
Evommune（NYSE: EVMN）が現金を賢明に活用することを期待しています。 - Moomoo
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), ServiceTitan, Inc. Class A (TTAN) and Evommune, Inc. (EVMN) - The Globe and Mail
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Australia
Evommune Scraps Itch Drug After Second Phase 2 Failure, Stock Slides 18% - finance.biggo.com
EVMN Maintains Rating by Leerink Partners -- Price Target Lowered to $22 - GuruFocus
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Why this company's stock took a hit just 10 months after its IPO - The Business Journals
Evommune’s EVO-756 fails dermatitis study; focus on migraine - BioWorld News
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Nigeria
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Canada
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com India
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Canada
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
RBC cuts Evommune stock price target on drug trial setback - Investing.com
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
Evommune Inc (EVMN) 財務データ
収益
当期純利益
現金流量
EPS
Evommune Inc (EVMN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| KIRSCH ARTHUR S | Director |
Jul 07 '26 |
Buy |
13.30 |
10,000 |
133,000 |
10,000 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Sale |
22.63 |
20,000 |
452,600 |
67,794 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Option Exercise |
3.84 |
1,488 |
5,714 |
47,891 |
| JANICE DREW | Officer |
Jun 22 '26 |
Proposed Sale |
21.36 |
20,000 |
427,200 |
0 |
| Patel Jeegar Pravinkumar | Chief Scientific Officer |
Jun 22 '26 |
Sale |
22.50 |
1,488 |
33,480 |
46,403 |
| Pena Luis C. | President & CEO |
Jun 22 '26 |
Sale |
22.71 |
7,438 |
168,917 |
630,458 |
| Drew Janice Suzann | Chief of Dev. Operations |
Jun 22 '26 |
Option Exercise |
3.15 |
20,000 |
63,063 |
87,794 |
| Cohen David E | Director |
Jun 02 '26 |
Sale |
20.33 |
6,056 |
123,094 |
17,609 |
| DAVID COHEN | Director |
Jun 02 '26 |
Proposed Sale |
22.17 |
9,258 |
205,250 |
0 |
| LUIS PENA | Director |
Jun 01 '26 |
Proposed Sale |
23.23 |
24,225 |
562,747 |
0 |
3.09%
0.72%
大文字化:
|
ボリューム (24 時間):